PubMed Health⌕ Search

Biomedical subjects

Manfred Jung

Publications and source records attributed to Manfred Jung.

22 records · Page 2Linked to original sources

A microplate reader-based nonisotopic histone deacetylase activity assay.

Recent years have brought an enormous increase in knowledge concerning the involvement of histone deacetylase (HDAC) in gene regulation and the potential use of its inhibitors in transcription therapy. This also stimulates research toward new methods for the determination of HDAC activity and thus the potency of potential inhibitors. We have previously succeeded in developing a nonisotopic assay for HDAC using a fluorescent coumarin derivative of epsilon-acetyllysine. Here we present plate reader-based quantitation as an alternative means for the determination of substrate conversion. A new validated assay procedure with a boradiazaindacene (BODIPY 530/550) rather than a coumarin internal standard was established to allow for fluorescence measurement without chromatographic separation. The method is equal in its sensitivity, accuracy, and precision to the previously published HPLC method. A comparison with a new commercially available homogeneous plate reader assay leads to similar inhibition constants for the HDAC inhibitor trichostatin A. The commercial assay has a higher throughput but its procedure for the detection of HDAC activity could not be applied to our enzyme preparation, while our substrate is also converted by HeLa HDAC. This indicates a broader range of potential applications for our system.

Animals↗

Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Inhibitors of histone deacetylase (HDAC) have been shown to induce terminal differentiation of human tumor cell lines and to have antitumor effects in vivo. We have prepared analogues of suberoylanilide hydroxamic acid (SAHA) and trichostatin A and have evaluated them in a human HDAC enzyme inhibition assay, a p21(waf1) (p21) promoter assay, and in monolayer growth inhibition assays. One compound, 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-benzamide, was found to affect the growth of a panel of eight human tumor cell lines differentially.

Antineoplastic Agents↗

Eosin Y as an internal standard for a plate reader-based quantitation of a histone deacetylase substrate.

Ongoing interest in histone deacetylase (HDAC) inhibitors as potential anticancer drugs and mechanistic tools for the study of gene regulation is driving the improvement of assay techniques for the determination of HDAC activity. We previously reported the first non-isotopic substrate for HDAC. A plate reader-based determination of the substrate conversion utilized a boraindacene as an internal standard which is no longer commercially available. We report here that Eosin Y is a suitable replacement for that purpose, leading to a validated HDAC assay with increased throughput.

Antineoplastic Agents↗

Comparative action of cobalt carbonyl complexes on cancer cells using human tumor xenografts.

We have previously shown that alkyne-cobalt carbonyl complexes inhibit the growth of human cancer cells. They were more active than dicobalt octacarbonyl, cobalt chloride or the free ligands. A difference in growth inhibition was observed among several cobalt complexes in two different cell lines indicating that the ligand may influence the activity of the complex. To further analyze cell type selectivity we compared the growth inhibition of two cobalt carbonyl complexes on eight different human tumor xenografts using a clonogenic assay which has been found to have a high predictive value, for further in vivo evaluation. For one compound as additional four cell lines were evaluated. Surprisingly we observed a large difference in the activity of the two complexes on cells originating from different tissues. Both compounds showed a comparable activity pattern indicating a common mechanism which seems to be different from that of the established metal-based anticancer agent cisplatin. Both complexes exceeded cisplatin in its in vitro anticancer activity.

Adenocarcinoma↗